CD11 Patch testing in vulval dermatoses

Abstract Patch testing is an important tool in the investigation of patients with vulval dermatoses, a significant impact on relevant identifiable allergen. There has been little research conducted this area, small studies suggesting higher rate positivity anogenital dermatoses (39–78%) vs. patch female generally (35–40%) (Woodruff CM, Trivedi MK, Botto N, Kornik R. Allergic contact dermatitis vulva. Dermatitis 2018; 29:233–43). also high clinically results (13–49%) (Vandeweege S, Debaene B, Lapeere H, Verstraelen H. A systematic review allergic and irritative vulva: most allergens/irritants role testing. Contact 2023; 88:249–62). The aetiology increased at site can be attributed to number factors. This includes intrinsic immunological characteristics skin, local elements including infection urine exposure, as well external behavioural lack site-specific guidance light propensity dermatoses. examined 54 patient records retrospectively University Hospital North Durham from 2016 2021 prospectively July December 2022 referred for symptoms. Forty-eight were included average age 51 years. Itch (48%) discomfort or soreness (28%) main symptoms which referred. frequently requested test batteries after British Standard Battery medicaments, then cortico­st­eroid. overall cohort was 73%, line available literature. common allergens nickel, followed by fragrances. Of positive tests, 48% relevant. Forty per cent had partial response withdrawal allergen, 8% complete response. Given psychosocial pruritus these patients, further population-based warranted standardize Additionally, low threshold referral should considered identify any element recalcitrant